FEMASYS INC FEMY
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-24.17
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.3M | -$18.6M | — | -$19.2M | $5.9M |
| 2024 | $1.6M | -$18.8M | — | -$20.2M | $2.3M |
| 2023 | $1.1M | -$14.2M | — | -$11.4M | $18.4M |
| 2022 | $1.2M | -$11.4M | $764,280 | -$11.1M | $15.2M |
| 2021 | $1.2M | -$7.5M | $809,305 | -$8.2M | $26.3M |
| 2020 | $1.0M | -$6.9M | $731,385 | -$4.9M | -$51.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -24.17 (distress)
- Working capital / assets 0.619
- Retained earnings / assets -7.037
- EBIT / assets -0.849
- Equity / liabilities 0.395
Source: SEC EDGAR filings · CIK 0001339005 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.